Skip Navigation

Cardiovascular Research 2007 75(2):261-274; doi:10.1016/j.cardiores.2007.04.004
This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Mann, G. E.
Right arrow Articles by Siow, R. C.M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mann, G. E.
Right arrow Articles by Siow, R. C.M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 2007, European Society of Cardiology

Activation of endothelial nitric oxide synthase by dietary isoflavones: Role of NO in Nrf2-mediated antioxidant gene expression

Giovanni E. Mann*, David J. Rowlands, Francois Y.L. Li, Patricia de Winter and Richard C.M. Siow

Cardiovascular Division, School of Medicine, King's College London, Franklin-Wilkins Building (Rm 3.01), 150 Stamford Street, London SE1 9NH, UK

* Corresponding author. Tel.: +44 20 7848 4306; fax: +44 20 7838 4500/3743. giovanni.mann{at}kcl.ac.uk

Received 16 February 2007; revised 31 March 2007; accepted 2 April 2007


   Abstract
Top
 Abstract
1. Introduction
 2. Vascular actions of...
 3. eNOS as a...
 4. Nitric oxide and...
 5. Conclusions
 References
 
The endothelium plays a key role in the maintenance of vascular homeostasis, and increased oxidative stress in vascular disease leads to reduced nitric oxide bioavailability and impaired endothelium-dependent relaxation of resistance vessels. Although epidemiological evidence suggests that diets containing high amounts of natural antioxidants afford protection against coronary heart disease (CHD), antioxidant supplementation trials have largely reported only marginal health benefits. There is controversy concerning the cardiovascular benefits of prolonged estrogen/progestin or soy isoflavone therapy for postmenopausal women and patients with an increased risk of CHD. Research on the potential health benefits of soy isoflavones and other polyphenols contained in red wine, green and black tea and dark chocolate developed rapidly during the 1990's, and recent clinical trials and studies in animal models and cultured endothelial cells provide important and novel insights into the mechanisms by which dietary polyphenols afford protection against oxidative stress. In this review, we highlight that NO and reactive oxygen radicals may mediate dietary polyphenol induced activation of Nrf2, which in turn triggers antioxidant response element (ARE) driven transcription of phase II detoxifying and antioxidant defense enzymes in vascular cells.

KEYWORDS Endothelial cells; Nitric oxide; Endothelial nitric oxide synthase; Caveolin-1; Heat shock protein 90; Soy isoflavones; Genistein; Daidzein; Equol; Red wine polyphenols; Tea polyphenols; Phosphoinositol 3-kinase; Extracellular signal-regulated kinase; cAMP; CREB; Nrf2; Antioxidant response element; Electrophile response element; Heme oxygenase-1; Estrogen receptors; Estrogen response element; Oxidative stress; Redox signaling


   1. Introduction
Top
 Abstract
 1. Introduction
2. Vascular actions of...
 3. eNOS as a...
 4. Nitric oxide and...
 5. Conclusions
 References
 
Nutrient–gene interactions have gained wide acceptance in the ‘post-genomic’ era, and nutrigenomic approaches are yielding insights at genomic, proteomic and metabolomic levels to evaluate the therapeutic potential of diets in the prevention and/or treatment of cardiovascular diseases [1]. Although diets containing natural antioxidants appear to afford protection against coronary heart disease (CHD), antioxidant supplementation provides only marginal health benefits [2], as evidenced by the Heart Outcomes Prevention Evaluation trial and its failure to show benefits of vitamin E supplementation in patients at high risk of CHD [3]. Polyphenols are organic compounds synthesized by plants, including tannins, lignans and flavonoids. Isoflavones are flavonoid compounds with both antioxidant and estrogenic properties, such as the soybean isoflavones genistein and daidzein which can behave as estrogen mimics [4]. The current interest in dietary soy isoflavones (‘phytoestrogens’) [4–9] is based on epidemiological evidence that an increased intake of soy isoflavones is associated with a lower incidence of CHD [9,10]. Soybean proteins and products contain significant amounts of the isoflavones genistein and daidzein, either in an unconjugated aglycone form or different glycoside conjugates [4]. Plasma concentrations of genistein are as low as 40 nM in humans consuming Westernized diets but can reach 4 µM in Japanese consuming a traditional soybean rich diet [4,10,11].

Polyphenols are also abundant in grape seeds and skins, and red wine is rich in proanthocyanidins (e.g. oligomers of catechin/epicatechin) [12]. Although resveratrol is found in the skin of grapes, its low abundance in red wine may limit its benefits for cardiovascular health. Nevertheless, resveratrol has been shown to extend the lifespan of mice on a high calorie diet [13]. Other rich sources of polyphenols are beans, apples, cranberries, hawthorn extract, green and black tea and dark chocolate [14–16]. As with dietary soy isoflavones, epidemiological studies attribute the lower incidence of CHD in France to an increased consumption of red wine rich in proanthocyanidins [17–19]. However, other factors may contribute to the ‘French’ paradox that populations with risk factors similar to those in the United States and northern Europe have significantly lower mortality due CHD [20]. Bioavailability of dietary polyphenols will be affected by rapid metabolism in the gastrointestinal tract and rates of intestinal absorption, with isoflavones absorbed more rapidly than catechins or proanthocyanidins [14,15].

Although randomized hormone replacement trials such as the Heart and Estrogen/progestin Replacement Study (HERS) and the Women's Health Initiative Study (WHI) reported a lack of benefit of combined estrogen/progestin therapy for cardiovascular disease [21,22], it is worth emphasizing that the conjugated equine estrogens used in these trials may not mimic the vascular actions of estradiol [23]. Thus research into alternatives for hormone replacement therapy has focused primarily on the potential cardiovascular benefits of natural polyphenolic compounds. The isoflavones genistein and daidzein are structurally similar to estrogen [4], and their preferential affinity for estrogen receptor (ER) β [24] provided a basis for evaluating the efficacy these isoflavones as modulators of vascular function without the undesired effects on breast and uterine tissue associated with prolonged estrogen therapy [21,22]. An increased intake of isoflavones by postmenopausal women in the Framingham Offspring Study highlighted a favorable cardiovascular risk profile [25], and the US Food and Drug Administration initially endorsed the health benefits of soy products [26]. However, in 2006 nutritional guidelines were revised by the American Heart Association [27], who concluded that the evidence for cardiovascular protection afforded by isoflavones is minimal and that health benefits of soy protein could be due to the high content of polyunsaturated fats (and low saturated fats), fiber, vitamins, and minerals [27].

Numerous clinical trials have examined the effects of isoflavone supplementation on vascular reactivity and arterial blood pressure in subjects who were elderly, overweight and/or smokers, potentially limiting interpretation of the cardiovascular health benefits of isoflavones. In addition, the outcome of several randomized trials with small cohorts of healthy subjects, hypertensive patients or postmenopausal women may be confounded by non-compliance with dietary guidelines, anti-hypertensive therapy and/or the variety of isoflavone formulations, their metabolic fate and bioavailability.

We have reviewed the evidence that soy isoflavones and polyphenols contained in red wine, green and black tea and dark chocolate influence vascular reactivity by targeting endothelial nitric oxide synthase (eNOS) and redox sensitive gene expression. Increased endothelium-dependent NO generation in response to laminar shear stress, vasoactive agonists and dietary polyphenols may modulate cellular sensor(s) for oxidative stress [28,29] and thereby increase NO bioavailability. Under conditions of increased oxidative or nitrosative stress, NO can react with superoxide anions (O2–) to form peroxynitrite [30]. NO and peroxynitrite enhance nuclear accumulation of Nrf2 (nuclear factor erythroid 2-related factor), a redox sensitive basic leucine-zipper transcription factor involved in antioxidant response element (ARE or electrophile response element, EpRE) dependent gene expression [31–34]. Under basal conditions, Nrf2 interacts with a cytosolic repressor protein Keap1 (Kelch ECH associating protein) limiting Nrf2 mediated gene expression [31]. In cells exposed to oxidative or xenobiotic stress, Nrf2 is released from Keap1 and translocates to the nucleus, where it activates ARE dependent transcription of phase II and antioxidant defense enzymes, such as NAD(P)H:quinone oxidoreductase, glutathione-S-transferase, glutathione peroxidase and heme oxygenase-1 [31–35].


   2. Vascular actions of soy isoflavones and other polyphenols in vivo
Top
 Abstract
 1. Introduction
 2. Vascular actions of...
3. eNOS as a...
 4. Nitric oxide and...
 5. Conclusions
 References
 
In two clinical studies, isoflavones have been shown to acutely modulate vascular reactivity in healthy postmenopausal women and male subjects in vivo [36,37]. Infusion of genistein or dihydroequol into the brachial artery, at concentrations achieved in populations consuming an isoflavone rich diet [4,11], evoked concentration- and endothelium-dependent increases in forearm blood flow (see Table 1) [36,37]. As a significant component of genistein mediated dilation was insensitive to L-NMMA [36], isoflavones also modulate vascular tone by inhibiting Ca2+ influx via L-type Ca2+ channels in vascular smooth muscle cells (Fig. 1) [38–40].


View this table:
[in this window]
[in a new window]

  		Table 1 Effects of dietary isoflavones and polyphenols on endothelium-dependent dilation and NO release in humans in vivo

 

Figure 1
View larger version (14K):
[in this window]
[in a new window]
[Download PowerPoint slide]
  		Fig. 1 Acute vascular relaxation mediated by dietary isoflavones and environmental estrogens. A–C, Rat aortic rings with an intact endothelium were preconstricted with phenylephrine (PE, 1 µM) and challenged with cumulative doses of vehicle or the daidzein metabolite equol (0.1–10 µM), in the absence (A) or presence (B) of the eNOS inhibitor L-NAME (100 µM, 30 min). C, Equol mediated relaxation as % of maximal PE-induced vasoconstriction, means±S.E.M., *p<0.05, **p<0.01 vs control, n=3 rats. Data replotted from [8]. D, perfusion of rat Langendorff heart with 4-octylphenol evokes a concentration-dependent fall in coronary perfusion pressure in the absence or presence of L-NAME (50 µM, not shown). E, A7r5 vascular smooth muscle cells were depolarized with 80 mM [K+]o after which 1 mM Ca2+ was added to the cuvette. Ratio of fluorescence at 340 nm and 380 nm was used to measure average [Ca2+]i responses to 1 mM Ca2+ in the presence of vehicle ({blacksquare}), 4-octylphenol ({square}) or the estrogen receptor antagonist ICI 182,780 (bullet) all at 10 µM. Responses relative to initial trace prior to 1 mM Ca2+ addition, means±S.E.M., n=3–6 coverslips. Data replotted from [38].

 
Longer-term supplementation with soy isoflavones improves arterial compliance in men and postmenopausal women [41–44], increases plasma nitrite/nitrate levels [45–48] and decreases plasma endothelin-1 levels [43,45,46]. However, some clinical studies have reported negligible effects of isoflavone supplementation on plasma endothelin-1 and/or nitrite levels [49,50], and the evidence for an improvement in plasma lipid profiles remains conflicting [21,48,51,52]. Several randomized, double-blind, placebo-controlled trials report cardiovascular benefits of longer-term (2–12 months) supplementation with genistein, tetrahydrodaidzein or soy isoflavones[42,44–46,48,53]. The consensus of such studies in healthy postmenopausal women is that isoflavone supplementation increases brachial artery flow-mediated dilation and improves systemic arterial compliance (Table 1) [41,42,44]. Despite numerous clinical studies, there is still controversy whether isoflavone supplementation lowers arterial blood pressure in vivo [42,44,53–55]. It is possible that vascular responses to isoflavone metabolites [54,55] may be limited to individuals capable of metabolizing ingested daidzein to equol [5,56,57]. In summary, the benefits of genistein supplementation on endothelial function have largely been observed in humans and animal models with mild to moderate hypertension [41,58–60].

We recently reported that feeding a soy protein diet rich in genistein and daidzein, known to interact with estrogen receptors [24], increases mRNA levels of eNOS and antioxidant enzymes in aged male rats [6]. In contrast, an isoflavone deficient diet fed from conception throughout adult life was associated with decreased GSH concentrations and mRNA levels for eNOS, MnSOD and cytochrome c oxidase, impaired endothelium-dependent relaxation and increased blood pressure in vivo (Table 2). Since a balanced isoflavone diet fed to rats from conception to 6 months of age has only marginal benefits for endothelial function [61], isoflavone supplementation may only restore vascular reactivity in aged animals or subjects with cardiovascular disease [6,62]. Chronic feeding of stroke-prone hypertensive rats with the flavonoid quercetin partially reverses elevated blood pressure and impaired endothelium-dependent relaxation in these animals [63]. The molecular mechanisms by which polyphenols diminish oxidative stress and reduce blood pressure in vivo remain to be elucidated. Nevertheless, vascular protection afforded by soy isoflavone diets may be related to an increased activity and/or expression of eNOS and NO bioavailability [9,64].


View this table:
[in this window]
[in a new window]

  		Table 2 Dietary soy isoflavones and polyphenols acutely activate eNOS in cultured endothelial cells and isolated arterial preparations

 
Randomized clinical studies in healthy human volunteers, smokers and patients with coronary artery disease have shown that consumption of black and green tea polyphenols or flavanol-rich chocolate/cocoa enhances flow-mediated brachial artery dilation within 1–24 h (Table 1) [65–71]. Clinical studies with healthy volunteers report that ingestion of flavanol-rich chocolate/cocoa results in a L-NAME sensitive peripheral vasodilation [72], increased insulin sensitivity and reduced blood pressure [70]. Moreover, patients with essential hypertension consuming flavanol-rich dark chocolate exhibit increased brachial artery flow-mediated dilation and a significant reduction in 24 h systolic blood pressure [71]. Only a limited number of clinical studies have measured plasma concentrations of nitroso species, 8-isoprostanes, epicatechin and/or epicatechin-7-O-gluronide (Table 1). Although flavanol-rich chocolate/cocoa increases plasma epicatechin concentrations and endothelium-dependent dilation and pure epicatechin mimics these effects [68,73], other bioactive components in chocolate could contribute to vascular relaxation in vivo. In this context, some studies report only limited relaxation of rat aortic rings [74] and eNOS activation in the EA.hy296 endothelial cell line [75] in response to catechin and epicatechin. Flavanols and green tea polyphenols have been reported to have antioxidant effects in human plasma [76] and modulate redox signaling in cells [77,78], providing additional mechanisms for increasing NO bioavailability.


   3. eNOS as a vascular target of soy isoflavones and other polyphenols
Top
 Abstract
 1. Introduction
 2. Vascular actions of...
 3. eNOS as a...
4. Nitric oxide and...
 5. Conclusions
 References
 
A series of seminal papers in the 1980's identified endothelium-derived relaxing factor (EDRF) as NO, which is synthesized by eNOS from the cationic amino acid L-arginine in the presence of molecular oxygen and other cofactors [79–81]. As a Ca2+/calmodulin (CaM)-dependent enzyme, eNOS is regulated by its association with the plasmalemmal scaffolding protein caveolin-1 [82,83], post-translational modification via phosphorylation by protein kinases and an interaction with the molecular chaperone heat shock protein 90 (Hsp90) [84–90]. Tethering of eNOS to caveolin-1 maintains the enzyme in an inactive state, and an elevation in intracellular Ca2+ leads to vasoactive agonists promoting association of CaM with eNOS and dissociation of the enzyme from caveolin-1 [91].

In addition to Ca2+-dependent activation of eNOS, laminar shear stress [87,92], adenosine [93], β2-adrenoceptor agonists [94], 17β-estradiol [95] and isoflavones [8] stimulate NO production via phosphorylation of eNOS at cytosolic Ca2+ levels, with some studies reporting rapid dissociation of eNOS from caveolin-1 and association with heat shock protein Hsp90 (Fig. 2). The major phosphorylation sites include Ser1177 (or Ser1179 in bovine cells) in the reductase domain and Thr495 and Thr497 in the CaM binding domain. Akt [96], protein kinase A [97], mitogen-activated protein kinases ERK1/2 [98] and p38MAPK [99] have all been reported to phosphorylate Ser1177. Phosphorylation at Thr495 antagonises binding of CaM to eNOS [100] and enzyme activation, and thus a concerted phosphorylation at Ser1177 and dephosphorylation of Thr495 occurs in response to different stimuli.


Figure 2
View larger version (14K):
[in this window]
[in a new window]
[Download PowerPoint slide]
  		Fig. 2 Ca2+-dependent and Ca2+-independent activation of eNOS and NO production in endothelial cells. Ca2+-dependent agonists rapidly stimulate Ca2+/calmodulin (CAM) dependent eNOS activation. Ca2+-independent stimuli such as fluid shear stress, adenosine, isoprenaline, estrogen and soy isoflavones acutely stimulate eNOS phosphorylation at resting cytosolic Ca2+ levels, involving activation of ERK1/2, PI(3)-kinase/Akt and/or PKA signaling pathways. Activation of eNOS involves rapid dissociation of the enzyme from membrane bound caveolin-1 (Cav-1) and association with Hsp90 and metabolism of the cationic amino acid L-arginine to NO and L-citrulline. Although ER{alpha} and ERβ (and truncated ER receptor) are expressed in HUVEC, rapid actions (<2 min) of isoflavones may not involve coupling of ER receptors to G{alpha}i in membrane caveolae. Adapted from [8].

 
Garcia-Cardena et al. [84] were the first to report an association of eNOS with the molecular chaperone protein Hsp90 in endothelial cells. Hsp90 belongs to a family of molecular chaperones that facilitate activation or correct folding of a wide range of proteins, including nuclear hormone receptors, protein kinases and eNOS [101–103]. Although Hsp90 does not affect eNOS dissociation from caveolin-1 in the absence of Ca2+/CaM, it facilitates CaM-mediated release of eNOS from caveolin [88]. Binding of Hsp90 to eNOS is essential for Akt-mediated activation of the enzyme, and importantly Hsp90 functions not only to recruit Akt to eNOS but also prevents proteosomal degradation of phosphoinositide-3-kinase 1 which activates Akt [90]. In the case of vascular endothelial growth factor (VEGF), Hsp90 modulates the transition from an initial Ca2+-dependent to a delayed and sustained phosphorylation-dependent activation of eNOS [104].

NO production can be inhibited by disrupting eNOS–Hsp90 association, using geldanamycin or radicicol, which bind to the N-terminal ATP-binding site of Hsp90 [105]. Although radicicol has been reported to inhibit src kinase, it initially inhibits Hsp90, which in turn destabilises src kinase. There are conflicting reports whether geldanamycin affects Akt activity or only the association of Akt with eNOS [90,104]. In the context of vascular oxidative stress, disruption of eNOS-Hsp90 can result in eNOS uncoupling and increased O2– production [85]. Geldanamycin, but not radicicol, redox cycles to generate O2– [106,107], however, the low levels of O2– generated may have a negligible impact on NO production [108]. Studies of Hsp90 interaction with purified tetrahydrobiopterin (BH4)-free eNOS revealed that BH4, and not Hsp90, inhibits Ca2+/CaM-dependent O2– formation from purified eNOS [109]. Importantly, depletion of BH4 in bovine aortic endothelial cells does not to alter Hsp90 levels or its interaction with eNOS, with increased O2– generation occurring independent of eNOS Ser1179 phosphorylation. Hsp90 protein levels are diminished in endothelial cells from pre-eclamptic pregnancies [110], which are characterized by an increased placental production of reactive oxygen species [111,112]. However, a recent review highlights that Hsp90 expression is upregulated under conditions of oxidative stress [113].

3.1 Acute activation of eNOS by soy isoflavones
The signaling pathways underlying eNOS activation by estrogens have been reviewed extensively [114–117], and co-localization of estrogen receptors (ER{alpha} and ERβ) with eNOS in membrane caveolae in endothelial cells provides a functional signaling unit for enzyme activation [118–120]. Hsp90 can interact directly with ERs, enabling 17β-estradiol to rapidly activate eNOS [121]. Although a subpopulation of estrogen-like receptors in the plasma membrane of endothelial cells may also mediate rapid activation of intracellular signaling pathways [8,122], there is no direct evidence that isoflavones interact with plasma membrane ‘estrogen receptors’.

As summarized in Table 2, isoflavones elicit both endothelium-dependent and -independent relaxation of preconstricted arterial rings in vitro, mimicking the acute dilator actions of genistein and dehydroequol in the human forearm vasculature [36,37]. We previously reported that the daidzein metabolite equol causes acute relaxation of rat preconstricted aortic rings [8]. Equol mediated relaxation was inhibited by L-NAME (Fig. 1A–C), whereas the environmental estrogenic pollutant 4-octylphenol and ICI 182,780 (not shown) reduced coronary perfusion pressure in isolated Langendorff hearts (Fig. 1D) via an inhibition of L-type Ca2+ channels in vascular smooth muscle (Fig. 1E, [38]).

As summarized in Fig. 2, low nanomolar concentrations of isoflavones rapidly stimulate NO release from cultured endothelial cells [8,123,124]. Our studies in human umbilical vein endothelial cells (HUVEC) established that genistein, daidzein and equol acutely (100 nM, 30 s–2 min) stimulate ERK1/2- and Akt-dependent eNOS phosphorylation at basal cytosolic Ca2+ levels. Isoflavone stimulated NO release was unaffected by the ER antagonists ICI 182,780 (Faslodex) and tamoxifen or uncoupling of G-protein receptors [8]. We further established that equol (100 nM) induces a rapid (2 min) association of eNOS with Hsp90 [8]. In contrast, genistein stimulated eNOS phosphorylation in bovine aortic endothelial cells (BAEC) occurs only after 5–10 min, involving activation of PKA but independent of extracellular signal-regulated kinase 1/2 or PI3-kinase [123]. Although genistein does not acutely elevate cAMP levels in HUVEC [8], treatment of BAEC with higher concentrations of genistein (5 µM, 30 min) increases cAMP levels and activates the transcription factor CREB involved in cAMP-mediated gene expression [124]. Thus, genistein stimulated eNOS activation may involve different signaling pathways in human and bovine endothelial cells. In the majority of studies with arterial ring preparations and endothelial cells rapid activation of eNOS by isoflavones is insensitive to inhibition by ICI 182,780 (Table 2). As high micromolar concentrations of genistein are well known to inhibit tyrosine kinase activity [125], caution is warranted in interpreting increased eNOS luciferase reporter activity in EA.hy296 endothelial cell line [126]. It is worth re-emphasizing that physiological plasma concentrations of genistein range between 0.1 nM to 1 µM [11].

3.2 Activation of eNOS by red wine polyphenols and flavanols in dark chocolate
Studies with isolated arterial rings have shown that red wine polyphenols and grape seed extracts increase endothelium/NO-dependent relaxation (see Table 2) [74,127–133]. Treatment of cultured endothelial cells with relatively high concentrations of resveratrol (30–100 µM) or red wine polyphenols increases eNOS mRNA levels and NO synthesis [75,134,135], however, two studies report negligible effects of resveratrol in human endothelial cells [135] and rat aortic rings [136]. Polyphenols contained in green and black tea and dark chocolate also activate eNOS in endothelial cells and augment endothelium-dependent relaxation in isolated arterial ring preparations [68,137–142]. Administration of black and green tea polyphenols for 3 weeks to stroke-prone hypertensive rats was associated with a decrease in systolic blood pressure in vivo [143], suggesting that elevated plasma catechin levels may stimulate endothelium-derived NO synthesis. As summarized in Table 2 and a recent review [144], there are reports that catechin and epicatechin elicit only limited vascular responses [74,75]. As recently reviewed [144], tea polyphenols modulate the activity of various kinases and have been reported to upregulate HO-1 expression in endothelial cells [145].


   4. Nitric oxide and peroxynitrite modulate Nfr2/ARE mediated redox signaling
Top
 Abstract
 1. Introduction
 2. Vascular actions of...
 3. eNOS as a...
 4. Nitric oxide and...
5. Conclusions
 References
 
Few studies have addressed the molecular and cellular targets of dietary polyphenols in vascular cells (Table 2). Estrogens and phytoestrogens can act as free radical scavengers [146], however, recent evidence indicates estrogens [147,148], isoflavones [6], red wine and tea polyphenols [75,134,135] and flavanol-rich dark chocolate can increase mRNA and protein levels for eNOS in endothelial cells (see Table 2). Moreover, polyphenols have been implicated in ARE-mediated gene transcription [147,148] and upregulation of MnSOD expression in vascular cells [149].

Induction of antioxidant genes is regulated through a cis-acting ARE element within the regulatory region of target genes [33]. The redox-sensitive basic leucine zipper protein transcription factor Nrf2 is involved in the regulation of many detoxification and antioxidant genes. Nrf2 belongs to the Cap-N-Collar family of transcription factors, forming heterodimers with small Maf proteins, with subsequent binding to ARE leading to transcriptional gene activation [28,31–33,35]. To our knowledge there are no reports suggesting that estrogens or isoflavones induce antioxidant genes via ER{alpha} or ERβ mediated transactivation of ARE. Moreover, genistein, daidzein and equol acutely activate eNOS phosphorylation and NO release independent of the classical estrogen receptors (Table 2) [8,123].

Exposure of endothelial cells to donors of NO and/or peroxynitrite leads to adaptive increases in glutathione (GSH) synthesis and Nrf2/ARE-regulated expression of genes encoding heme oxygenase-1 (HO-1), {gamma}-glutamylcysteine synthetase ({gamma}-GCS) and the L-cystine anionic amino transporter xCT [150–152]. The microsomal enzyme HO-1 metabolizes heme to generate biliverdin/bilirubin and carbon monoxide, which like NO can inhibit platelet aggregation and act as a vasodilator when the bioavailability of NO is limited [153–155]. Biliverdin is subsequently converted by biliverdin reductase to bilirubin, a chain-breaking antioxidant which can scavenge lipid peroxyl radicals [156]. L-cystine transport is a rate-limiting for GSH biosynthesis in endothelial cells exposed to oxidative stress [157,158], providing an adaptive mechanism to reduce oxidative stress associated with lipid peroxidation. Treatment of bovine aortic endothelial cells S-nitrosopenicillamine or SIN-1 (~0.1–1 mM, 16–18 h) stimulates L-cystine transport [150], suggesting that donors of NO and peroxynitrite activate Nrf2/ARE mediated expression of xCT transporter. In the same cell type, spermine NONOate causes rapid nuclear translocation of Nrf2 (2–4 h), phosphorylation of ERK1/2, p38 and JNK mitogen-activated protein kinases and increased activity/expression of xCT and HO-1 [151]. Inhibitors of MAPK cascades reduce Nrf2 translocation, implicating MAPK as modulators of NO induced Nrf2/ARE signaling [159–161]. Notably, pretreatment of endothelial cells with the antioxidant N-acetylcysteine only decreases NO stimulated HO-1 expression by <40% [151].

Accumulating evidence suggests that the Keap1-Nrf2 complex constitutes a sensor of oxidative stress involved in triggering ARE mediated gene expression to restore the cellular redox status [28]. If NO were able to S-nitrosylate ‘oxidant sensing’ cysteine residues in the intervening region of Keap 1 [162], this would promote dissociation of Nrf2 from the complex and translocation into the nucleus to initiate ARE mediated gene transcription. In this context, studies in neuroblastoma cells have shown that NO stimulated activation of Nrf2/ARE leads to transcriptional up-regulation of NQO1 to counteract NO-induced apoptosis [163].


   5. Conclusions
Top
 Abstract
 1. Introduction
 2. Vascular actions of...
 3. eNOS as a...
 4. Nitric oxide and...
 5. Conclusions
References
 
Our survey of clinical supplementation trials and studies with isolated vascular rings and cultured endothelial cells (Tables 1 and 2Go) highlights that soy isoflavones and polyphenols contained in red wine, green and black tea and dark chocolate rapidly activate intracellular kinase signaling pathways, resulting in eNOS activation and/or increased NO synthesis. Reports on the effects of antioxidants and polyphenols on redox sensitive gene expression in endothelial cells are limited, and published DNA microarray studies have not correlated changes in mRNA expression with altered enzyme activity or endothelial function [164].

The schematic model in Fig. 3 summarizes potential mechanisms by which polyphenols contained in soy, red wine, tea and dark chocolate elicit transactivation of vasoactive (e.g. eNOS) and antioxidant defense (e.g. HO-1, NQO1, xCT) genes. Further studies are required to establish whether soy isoflavones bind specifically to plasma membrane estrogen receptors, including the classical receptors ER{alpha} and ERβ [24], truncated estrogen receptors [122] and/or GPR30, a G-protein coupled receptor with characteristics of membrane estrogen binding activity [165]. To our knowledge there is no definitive evidence that polyphenols in red wine, green or black tea and dark chocolate interact with a membrane receptor to activate intracellular signaling pathways.


Figure 3
View larger version (26K):
[in this window]
[in a new window]
[Download PowerPoint slide]
  		Fig. 3 Nitric oxide as a mediator of polyphenol induced transcriptional activation of antioxidant genes. Isoflavones, estrogens and other polyphenols activate intracellular kinase cascades, leading to acute activation of eNOS and NO and/or ROS generation. Increased NO, ROS or peroxynitrite levels will modify cysteine residues on Keap-1 leading to dissociation and nuclear translocation of the redox sensitive transcription factor Nrf2. Nrf2 binds to the antioxidant response element (ARE) or electrophile response element (EpRE) in the promoter region of target genes (e.g. phase II and antioxidant enzymes NQO1, HO-1, GPx) whilst estrogen receptors bind to estrogen response element (ERE) to enhance eNOS expression. Induction of other antioxidant genes such as MnSOD may involve rapid phosphorylation of ERK1/2 and I{kappa}B and translocation of the p50 subunit of NF{kappa}B to the nucleus and transactivation of MnSOD expression. Adapted from [7,8].

 
Both laminar shear stress [166,167] and polyphenols (see Table 2 and [168]) increase NO and ROS production in endothelial cells. Exposure of human endothelial cells to laminar shear stress, but not oscillatory flow, is associated with Nrf2/ARE mediated induction of NADPH quinone oxidoreductase 1 (NQO1) and heme oxygenase-1 (HO-1) [169,170]. Activation of Nrf2/ARE mediated transcription by laminar shear stress does not apparently involve NO, whereas inhibitors of xanthine oxidase, NADPH oxidase and the mitochondrial respiratory chain suppress shear induced antioxidant gene expression [171].

Since polyphenols may modulate eNOS via O2– mediated activation of src kinase [133], it seems relevant to further investigate the source(s) and role(s) of O2– and other ROS in soy isoflavone mediated activation of eNOS and antioxidant genes. Under conditions of oxidative stress, upregulation of Hsp90 expression and increased intracellular Ca2+ will promote turnover and proteosomal degradation of proteins such as calmodulin and eNOS [113,172] and thereby affect NO bioavailability. We hypothesize that the ability of dietary polyphenols to generate both NO and ROS in endothelial cells and activate ARE/EpRE mediated gene expression [173] underlies their cardioprotective properties.

In summary, dietary polyphenols may counteract oxidative stress in vascular and inflammatory diseases [174] by modulating key redox sensitive gene transcription via NF-{kappa}B [7] and Nrf2/ARE [175,176] signaling pathways. In view of the inherent genetic variability and the potential for non-compliance in human supplementation trials, studies in genetically identical mice (wildtype and knockout) should provide important insights into the mechanisms by which dietary soy isoflavones and other polyphenols regulate antioxidant gene expression in endothelial and other vascular cell types, including smooth muscle cells, monocytes and platelets.

Time for primary review 20 days


   Acknowledgements
 
We gratefully acknowledge research funding from the British Heart Foundation (FS/9075, FS/05/005), Biotechnology and Biological Sciences Research Council (BBS/S/K/204/11207), Medical Research Council (G9820929), Heart Research UK (RG2489/04/08), Wing Yip & Brothers Charitable Foundation, Overseas Research Scholarship (20040554030), King's College London and Hong Kong Alumni Association, and EU COST Action B35. We are indebted to our collaborators whose names appear in the cited publications.


   References
Top
 Abstract
 1. Introduction
 2. Vascular actions of...
 3. eNOS as a...
 4. Nitric oxide and...
 5. Conclusions
 References
 

  1. Muller M., Kersten S. Nutrigenomics: goals and strategies. Nat Rev Genet (2003) 4:315–322.[CrossRef][ISI][Medline]
  2. Halliwell B. The antioxidant paradox. Lancet (2000) 355:1179–1180.[CrossRef][ISI][Medline]
  3. Yusuf S., Dagenais G., Pogue J., Bosch J., Sleight P. Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med (2000) 342:154–160.[Abstract/Free Full Text]
  4. Setchell K.D. Phytoestrogens: the biochemistry, physiology, and implications for human health of soy isoflavones. Am J Clin Nutr (1998) 68:1333S–1346S.[Abstract]
  5. Cassidy A., Brown J.E., Hawdon A., Faughnan M.S., King L.J., Millward J., et al. Factors affecting the bioavailability of soy isoflavones in humans after ingestion of physiologically relevant levels from different soy foods. J Nutr (2006) 136:45–51.[Abstract/Free Full Text]
  6. Mahn K., Borras C., Knock G.A., Taylor P., Khan I.Y., Sugden D., et al. Dietary soy isoflavone induced increases in antioxidant and eNOS gene expression lead to improved endothelial function and reduced blood pressure in vivo. FASEB J (2005) 19:1755–1757.[Abstract/Free Full Text]
  7. Borras C., Gambini J., Gomez-Cabrera M.C., Sastre J., Pallardo F.V., Mann G.E., et al. Genistein, a soy isoflavone, up-regulates expression of antioxidant genes: involvement of estrogen receptors, ERK1/2, and NFkappaB. FASEB J (2006) 20:2136–2138.[Abstract/Free Full Text]
  8. Joy S., Siow R.C., Rowlands D.J., Becker M., Wyatt A.W., Aaronson P.I., et al. The isoflavone equol mediates rapid vascular relaxation: Ca2+-independent activation of endothelial nitric-oxide synthase/Hsp90 involving ERK1/2 and Akt phosphorylation in human endothelial cells. J Biol Chem (2006) 281:27335–27345.[Abstract/Free Full Text]
  9. Lissin L.W., Cooke J.P. Phytoestrogens and cardiovascular health. J Am Coll Cardiol (2000) 35:1403–1410.[Abstract/Free Full Text]
  10. Adlercreutz H., Mazur W. Phyto-oestrogens and Western diseases. Ann Med (1997) 29:95–120.[ISI][Medline]
  11. Adlercreutz H., Markkanen H., Watanabe S. Plasma concentrations of phyto-oestrogens in Japanese men. Lancet (1993) 342:1209–1210.[CrossRef][ISI][Medline]
  12. Waterhouse A.L. Wine phenolics. Ann NY Acad Sci (2002) 957:21–36.[Abstract/Free Full Text]
  13. Baur J.A., Pearson K.J., Price N.L., Jamieson H.A., Lerin C., Kalra A., et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature (2006) 444:337–342.[CrossRef][Medline]
  14. Manach C., Williamson G., Morand C., Scalbert A., Remesy C. Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies. Am J Clin Nutr (2005) 81:230S–242S.[Abstract/Free Full Text]
  15. Williamson G., Manach C. Bioavailability and bioefficacy of polyphenols in humans. II. Review of 93 intervention studies. Am J Clin Nutr (2005) 81:243S–255S.[Abstract/Free Full Text]
  16. Sies H., Stahl W., Sevanian A. Nutritional, dietary and postprandial oxidative stress. J Nutr (2005) 135:969–972.[Abstract/Free Full Text]
  17. Stoclet J.C., Chataigneau T., Ndiaye M., Oak M.H., El B.J., Chataigneau M., et al. Vascular protection by dietary polyphenols. Eur J Pharmacol (2004) 500:299–313.[CrossRef][ISI][Medline]
  18. Rasmussen S.E., Frederiksen H., Struntze K.K., Poulsen L. Dietary proanthocyanidins: occurrence, dietary intake, bioavailability, and protection against cardiovascular disease. Mol Nutr Food Res (2005) 49:159–174.[CrossRef][ISI][Medline]
  19. Corder R., Mullen W., Khan N.Q., Marks S.C., Wood E.G., Carrier M.J., et al. Oenology: red wine procyanidins and vascular health. Nature (2006) 444:566.[CrossRef][Medline]
  20. Renaud S., de Lorgeril M. Wine, alcohol, platelets, and the French paradox for coronary heart disease. Lancet (1992) 339:1523–1526.[CrossRef][ISI][Medline]
  21. Anderson G.L., Limacher M., Assaf A.R., Bassford T., Beresford S.A., Black H., et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA (2004) 291:1701–1712.[Abstract/Free Full Text]
  22. Hulley S.B., Grady D. The WHI estrogen-alone trial—do things look any better? JAMA (2004) 291:1769–1771.[Free Full Text]
  23. Dubey R.K., Imthurn B., Barton M., Jackson E.K. Vascular consequences of menopause and hormone therapy: importance of timing of treatment and type of estrogen. Cardiovasc Res (2005) 66:295–306.[Abstract/Free Full Text]
  24. Kuiper G.G., Carlsson B., Grandien K., Enmark E., Haggblad J., Nilsson S., et al. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology (1997) 138:863–870.[Abstract/Free Full Text]
  25. de Kleijn M.J., van der Schouw Y.T., Wilson P.W., Grobbee D.E., Jacques P.F. Dietary intake of phytoestrogens is associated with a favorable metabolic cardiovascular risk profile in postmenopausal U.S. women: the Framingham study. J Nutr (2002) 132:276–282.[Abstract/Free Full Text]
  26. Erdman J.W. Jr. AHA Science Advisory: Soy protein and cardiovascular disease: A statement for healthcare professionals from the Nutrition Committee of the AHA. Circulation (2000) 102:2555–2559.[Free Full Text]
  27. Sacks F.M., Lichtenstein A., Van H.L., Harris W., Kris-Etherton P., Winston M. Soy protein, isoflavones, and cardiovascular health: an American Heart Association Science Advisory for professionals from the Nutrition Committee. Circulation (2006) 113:1034–1044.[Abstract/Free Full Text]
  28. McMahon M., Thomas N., Itoh K., Yamamoto M., Hayes J.D. Redox-regulated turnover of Nrf2 is determined by at least two separate protein domains, the redox-sensitive Neh2 degron and the redox-insensitive Neh6 degron. J Biol Chem (2004) 279:31556–31567.[Abstract/Free Full Text]
  29. Liu H., Colavitti R., Rovira I.I., Finkel T. Redox-dependent transcriptional regulation. Circ Res (2005) 97:967–974.[Abstract/Free Full Text]
  30. Pacher P., Beckman J.S., Liaudet L. Nitric oxide and peroxynitrite in health and disease. Physiol Rev (2007) 87:315–424.[Abstract/Free Full Text]
  31. Itoh K., Wakabayashi N., Katoh Y., Ishii T., Igarashi K., Engel J.D., et al. Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. Genes Dev (1999) 13:76–86.[Abstract/Free Full Text]
  32. Ishii T., Itoh K., Takahashi S., Sato H., Yanagawa T., Katoh Y., et al. Transcription factor Nrf2 coordinately regulates a group of oxidative stress-inducible genes in macrophages. J Biol Chem (2000) 275:16023–16029.[Abstract/Free Full Text]
  33. Nguyen T., Sherratt P.J., Pickett C.B. Regulatory mechanisms controlling gene expression mediated by the antioxidant response element. Annu Rev Pharmacol Toxicol (2003) 43:233–260.[CrossRef][ISI][Medline]
  34. Ishii T., Itoh K., Ruiz E., Leake D.S., Unoki H., Yamamoto M., et al. Role of Nrf2 in the regulation of CD36 and stress protein expression in murine macrophages: activation by oxidatively modified LDL and 4-hydroxynonenal. Circ Res (2004) 94:609–616.[Abstract/Free Full Text]
  35. Kensler T.W., Wakabayashi N., Biswal S. Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. Annu Rev Pharmacol Toxicol (2007) 47:89–116.[CrossRef][ISI][Medline]
  36. Walker H.A., Dean T.S., Sanders T.A., Jackson G., Ritter J.M., Chowienczyk P.J. The phytoestrogen genistein produces acute nitric oxide dependent dilation of human forearm vasculature with similar potency to 17beta-estradiol. Circulation (2001) 103:258–262.[ISI][Medline]
  37. Chin-Dusting J.P., Boak L., Husband A., Nestel P.J. The isoflavone metabolite dehydroequol produces vasodilatation in human resistance arteries via a nitric oxide dependent mechanism. Atherosclerosis (2004) 176:45–48.[CrossRef][ISI][Medline]
  38. Ruehlmann D.O., Steinert J.R., Valverde M.A., Jacob R., Mann G.E. Environmental estrogenic pollutants induce acute vascular relaxation by inhibiting L-type Ca2+ channels in smooth muscle cells. FASEB J (1998) 12:613–619.[Abstract/Free Full Text]
  39. Figtree G.A., Griffiths H., Lu Y.Q., Webb C.M., MacLeod K., Collins P. Plant-derived estrogens relax coronary arteries in vitro by a calcium antagonistic mechanism. J Am Coll Cardiol (2000) 35:1977–1985.[Abstract/Free Full Text]
  40. Mishra S.K., Abbot S.E., Choudhury Z., Cheng M., Khatab N., Maycock N.J., et al. Endothelium-dependent relaxation of rat aorta and main pulmonary artery by the phytoestrogens genistein and daidzein. Cardiovasc Res (2000) 46:539–546.[Abstract/Free Full Text]
  41. Teede H.J., McGrath B.P., DeSilva L., Cehun M., Fassoulakis A., Nestel P.J. Isoflavones reduce arterial stiffness: a placebo-controlled study in men and postmenopausal women. Arterioscler Thromb Vasc Biol (2003) 23:1066–1071.[Abstract/Free Full Text]
  42. Nestel P.J., Yamashita T., Sasahara T., Pomeroy S., Dart A., Komesaroff P., et al. Soy isoflavones improve systemic arterial compliance but not plasma lipids in menopausal and perimenopausal women. Arterioscler Thromb Vasc Biol (1997) 17:3392–3398.[Abstract/Free Full Text]
  43. Altavilla D., Crisafulli A., Marini H., Esposito M., D'Anna R., Corrado F., et al. Cardiovascular effects of the phytoestrogen genistein. Curr Med Chem Cardiovasc Hematol Agents (2004) 2:179–186.[CrossRef][Medline]
  44. Nestel P., Fujii A., Zhang L. An isoflavone metabolite reduces arterial stiffness and blood pressure in overweight men and postmenopausal women. Atherosclerosis (2006) 192:184–189.[CrossRef][ISI][Medline]
  45. Squadrito F., Altavilla D., Morabito N., Crisafulli A., D'Anna R., Corrado F., et al. The effect of the phytoestrogen genistein on plasma nitric oxide concentrations, endothelin-1 levels and endothelium dependent vasodilation in postmenopausal women. Atherosclerosis (2002) 163:339–347.[CrossRef][ISI][Medline]
  46. Hallund J., Bugel S., Tholstrup T., Ferrari M., Talbot D., Hall W.L., et al. Soya isoflavone-enriched cereal bars affect markers of endothelial function in postmenopausal women. Br J Nutr (2006) 95:1120–1126.[CrossRef][ISI][Medline]
  47. Pereira I.R., Faludi A.A., Aldrighi J.M., Bertolami M.C., Saleh M.H., Silva R.A., et al. Effects of soy germ isoflavones and hormone therapy on nitric oxide derivatives, low-density lipoprotein oxidation, and vascular reactivity in hypercholesterolemic postmenopausal women. Menopause (2006) 13:942–950.[CrossRef][ISI][Medline]
  48. Squadrito F., Altavilla D., Crisafulli A., Saitta A., Cucinotta D., Morabito N., et al. Effect of genistein on endothelial function in postmenopausal women: a randomized, double-blind, controlled study. Am J Med (2003) 114:470–476.[CrossRef][ISI][Medline]
  49. Nikander E., Metsa-Heikkila M., Tiitinen A., Ylikorkala O. Evidence of a lack of effect of a phytoestrogen regimen on the levels of C-reactive protein, E-selectin, and nitrate in postmenopausal women. J Clin Endocrinol Metab (2003) 88:5180–5185.[Abstract/Free Full Text]
  50. Pereira I.R., Faludi A.A., Aldrighi J.M., Bertolami M.C., Saleh M.H., Silva R.A., et al. Effects of soy germ isoflavones and hormone therapy on nitric oxide derivatives, low-density lipoprotein oxidation, and vascular reactivity in hypercholesterolemic postmenopausal women. Menopause (2006) 13:942–950.[CrossRef][ISI][Medline]
  51. Simons L.A., von K.M., Simons J., Celermajer D.S. Phytoestrogens do not influence lipoprotein levels or endothelial function in healthy, postmenopausal women. Am J Cardiol (2000) 85:1297–1301.[CrossRef][ISI][Medline]
  52. Lissin L.W., Oka R., Lakshmi S., Cooke J.P. Isoflavones improve vascular reactivity in post-menopausal women with hypercholesterolemia. Vasc Med (2004) 9:26–30.[Abstract/Free Full Text]
  53. Teede H.J., Dalais F.S., Kotsopoulos D., Liang Y.L., Davis S., McGrath B.P. Dietary soy has both beneficial and potentially adverse cardiovascular effects: a placebo-controlled study in men and postmenopausal women. J Clin Endocrinol Metab (2001) 86:3053–3060.[Abstract/Free Full Text]
  54. Kreijkamp-Kaspers S., Kok L., Bots M.L., Grobbee D.E., van der Schouw Y.T. Dietary phytoestrogens and vascular function in postmenopausal women: a cross-sectional study. J Hypertens (2004) 22:1381–1388.[CrossRef][ISI][Medline]
  55. Kreijkamp-Kaspers S., Kok L., Bots M.L., Grobbee D.E., Lampe J.W., van der Schouw Y.T. Randomized controlled trial of the effects of soy protein containing isoflavones on vascular function in postmenopausal women. Am J Clin Nutr (2005) 81:189–195.[Abstract/Free Full Text]
  56. Setchell K.D., Clerici C., Lephart E.D., Cole S.J., Heenan C., Castellani D., et al. S-equol, a potent ligand for estrogen receptor beta, is the exclusive enantiomeric form of the soy isoflavone metabolite produced by human intestinal bacterial flora. Am J Clin Nutr (2005) 81:1072–1079.[Abstract/Free Full Text]
  57. Vergne S., Titier K., Bernard V., Asselineau J., Durand M., Lamothe V., et al. Bioavailability and urinary excretion of isoflavones in humans: effects of soy-based supplements formulation and equol production. J Pharm Biomed Anal (2006) 43:1488–1494.[CrossRef][ISI][Medline]
  58. Rivas M., Garay R.P., Escanero J.F., Cia P. Jr., Cia P., Alda J.O. Soy milk lowers blood pressure in men and women with mild to moderate essential hypertension. J Nutr (2002) 132:1900–1902.[Abstract/Free Full Text]
  59. Vera R., Sanchez M., Galisteo M., Villar I.C., Jimenez R., Zarzuelo A., et al. Chronic administration of genistein improves endothelial dysfunction in spontaneously hypertensive rats: involvement of eNOS, caveolin and calmodulin expression and NADPH oxidase activity. Clin Sci (Lond) (2007) 112:183–191.[Medline]
  60. Xu J.W., Ikeda K., Yamori Y. Genistein inhibits expressions of NADPH oxidase p22phox and angiotensin II type 1 receptor in aortic endothelial cells from stroke-prone spontaneously hypertensive rats. Hypertens Res (2004) 27:675–683.[CrossRef][ISI][Medline]
  61. Douglas G., Armitage J.A., Taylor P.D., Lawson J.R., Mann G.E., Poston L. Cardiovascular consequences of life-long exposure to dietary isoflavones in the rat. J Physiol (2006) 571:477–487.[Abstract/Free Full Text]
  62. Trujillo J., Ramirez V., Perez J., Torre-Villalvazo I., Torres N., Tovar A.R., et al. Renal protection by a soy diet in obese Zucker rats is associated with restoration of nitric oxide generation. Am J Physiol Renal Physiol (2005) 288:F108–F116.[Abstract/Free Full Text]
  63. Sanchez M., Galisteo M., Vera R., Villar I.C., Zarzuelo A., Tamargo J., et al. Quercetin downregulates NADPH oxidase, increases eNOS activity and prevents endothelial dysfunction in spontaneously hypertensive rats. J Hypertens (2006) 24:75–84.[Medline]
  64. Hwang J., Wang J., Morazzoni P., Hodis H.N., Sevanian A. The phytoestrogen equol increases nitric oxide availability by inhibiting superoxide production: an antioxidant mechanism for cell-mediated LDL modification. Free Radic Biol Med (2003) 34:1271–1282.[CrossRef][ISI][Medline]
  65. Duffy S.J., Keaney J.F. Jr., Holbrook M., Gokce N., Swerdloff P.L., Frei B., et al. Short- and long-term black tea consumption reverses endothelial dysfunction in patients with coronary artery disease. Circulation (2001) 104:151–156.[Abstract/Free Full Text]
  66. Heiss C., Kleinbongard P., Dejam A., Perre S., Schroeter H., Sies H., et al. Acute consumption of flavanol-rich cocoa and the reversal of endothelial dysfunction in smokers. J Am Coll Cardiol (2005) 46:1276–1283.[Abstract/Free Full Text]
  67. Heiss C., Schroeter H., Balzer J., Kleinbongard P., Matern S., Sies H., et al. Endothelial function, nitric oxide, and cocoa flavanols. J Cardiovasc Pharmacol (2006) 47(Suppl_2):S128–S135.[CrossRef][ISI][Medline]
  68. Schroeter H., Heiss C., Balzer J., Kleinbongard P., Keen C.L., Hollenberg N.K., et al. (–)-Epicatechin mediates beneficial effects of flavanol-rich cocoa on vascular function in humans. Proc Natl Acad Sci U S A (2006) 103:1024–1029.[Abstract/Free Full Text]
  69. Vlachopoulos C., Aznaouridis K., Alexopoulos N., Economou E., Andreadou I., Stefanadis C. Effect of dark chocolate on arterial function in healthy individuals. Am J Hypertens (2005) 18:785–791.[CrossRef][ISI][Medline]
  70. Grassi D., Lippi C., Necozione S., Desideri G., Ferri C. Short-term administration of dark chocolate is followed by a significant increase in insulin sensitivity and a decrease in blood pressure in healthy persons. Am J Clin Nutr (2005) 81:611–614.[Abstract/Free Full Text]
  71. Grassi D., Necozione S., Lippi C., Croce G., Valeri L., Pasqualetti P., et al. Cocoa reduces blood pressure and insulin resistance and improves endothelium-dependent vasodilation in hypertensives. Hypertension (2005) 46:398–405.[Abstract/Free Full Text]
  72. Fisher N.D., Hughes M., Gerhard-Herman M., Hollenberg N.K. Flavanol-rich cocoa induces nitric-oxide-dependent vasodilation in healthy humans. J Hypertens (2003) 21:2281–2286.[CrossRef][Medline]
  73. Engler M.B., Engler M.M., Chen C.Y., Malloy M.J., Browne A., Chiu E.Y., et al. Flavonoid-rich dark chocolate improves endothelial function and increases plasma epicatechin concentrations in healthy adults. J Am Coll Nutr (2004) 23:197–204.[Abstract/Free Full Text]
  74. Mendes A., Desgranges C., Cheze C., Vercauteren J., Freslon J.L. Vasorelaxant effects of grape polyphenols in rat isolated aorta. Possible involvement of a purinergic pathway. Fundam Clin Pharmacol (2003) 17:673–681.[CrossRef][ISI][Medline]
  75. Wallerath T., Li H., Godtel-Ambrust U., Schwarz P.M., Forstermann U. A blend of polyphenolic compounds explains the stimulatory effect of red wine on human endothelial NO synthase. Nitric Oxide (2005) 12:97–104.[CrossRef][ISI][Medline]
  76. Locher R., Emmanuele L., Suter P.M., Vetter W., Barton M. Green tea polyphenols inhibit human vascular smooth muscle cell proliferation stimulated by native low-density lipoprotein. Eur J Pharmacol (2002) 434:1–7.[CrossRef][ISI][Medline]
  77. Fraga C.G. Cocoa, diabetes, and hypertension: should we eat more chocolate? Am J Clin Nutr (2005) 81:541–542.[Free Full Text]
  78. Mackenzie G.G., Carrasquedo F., Delfino J.M., Keen C.L., Fraga C.G., Oteiza P.I. Epicatechin, catechin, and dimeric procyanidins inhibit PMA-induced NF-kappaB activation at multiple steps in Jurkat T cells. FASEB J (2004) 18:167–169.[Abstract/Free Full Text]
  79. Furchgott R.F., Zawadzki J.V. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature (1980) 288:373–376.[CrossRef][Medline]
  80. Ignarro L.J., Buga G.M., Wood K.S., Byrns R.E., Chaudhuri G. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci U S A (1987) 84:9265–9269.[Abstract/Free Full Text]
  81. Palmer R.M., Ferrige A.G., Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature (1987) 327:524–526.[CrossRef][Medline]
  82. Garcia-Cardena G., Oh P., Liu J., Schnitzer J.E., Sessa W.C. Targeting of nitric oxide synthase to endothelial cell caveolae via palmitoylation: implications for nitric oxide signaling. Proc Natl Acad Sci U S A (1996) 93:6448–6453.[Abstract/Free Full Text]
  83. Shaul P.W., Smart E.J., Robinson L.J., German Z., Yuhanna I.S., Ying Y., et al. Acylation targets endothelial nitric-oxide synthase to plasmalemmal caveolae. J Biol Chem (1996) 271:6518–6522.[Abstract/Free Full Text]
  84. Garcia-Cardena G., Fan R., Shah V., Sorrentino R., Cirino G., Papapetropoulos A., et al. Dynamic activation of endothelial nitric oxide synthase by Hsp90. Nature (1998) 392:821–824.[CrossRef][Medline]
  85. Pritchard K.A. Jr., Ackerman A.W., Gross E.R., Stepp D.W., Shi Y., Fontana J.T., et al. Heat shock protein 90 mediates the balance of nitric oxide and superoxide anion from endothelial nitric-oxide synthase. J Biol Chem (2001) 276:17621–17624.[Abstract/Free Full Text]
  86. Brouet A., Sonveaux P., Dessy C., Moniotte S., Balligand J.L., Feron O. Hsp90 and caveolin are key targets for the proangiogenic nitric oxide-mediated effects of statins. Circ Res (2001) 89:866–873.[Abstract/Free Full Text]
  87. Boo Y.C., Jo H. Flow-dependent regulation of endothelial nitric oxide synthase: role of protein kinases. Am J Physiol Cell Physiol (2003) 285:C499–C508.[Abstract/Free Full Text]
  88. Takahashi S., Mendelsohn M.E. Synergistic activation of endothelial nitric-oxide synthase (eNOS) by HSP90 and Akt: calcium-independent eNOS activation involves formation of an HSP90-Akt-CaM-bound eNOS complex. J Biol Chem (2003) 278:30821–30827.[Abstract/Free Full Text]
  89. Venema R.C., Venema V.J., Ju H., Harris M.B., Snead C., Jilling T., et al. Novel complexes of guanylate cyclase with heat shock protein 90 and nitric oxide synthase. Am J Physiol Heart Circ Physiol (2003) 285:H669–H678.[Abstract/Free Full Text]
  90. Wei Q., Xia Y. Roles of 3-phosphoinositide-dependent kinase 1 in the regulation of endothelial nitric-oxide synthase phosphorylation and function by heat shock protein 90. J Biol Chem (2005) 280:18081–18086.[Abstract/Free Full Text]
  91. Ghosh S., Gachhui R., Crooks C., Wu C., Lisanti M.P., Stuehr D.J. Interaction between caveolin-1 and the reductase domain of endothelial nitric-oxide synthase. Consequences for catalysis. J Biol Chem (1998) 273:22267–22271.[Abstract/Free Full Text]
  92. Fleming I., Bauersachs J., Fisslthaler B., Busse R. Ca2+-independent activation of the endothelial nitric oxide synthase in response to tyrosine phosphatase inhibitors and fluid shear stress. Circ Res (1998) 82:686–695.[Abstract/Free Full Text]
  93. Wyatt A.W., Steinert J.R., Wheeler-Jones C.P., Morgan A.J., Sugden D., Pearson J.D., et al. Early activation of the p42/p44MAPK pathway mediates adenosine-induced nitric oxide production in human endothelial cells: a novel calcium-insensitive mechanism. FASEB J (2002) 16:1584–1594.[Abstract/Free Full Tex